4.2 Article

Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative

Journal

FAMILIAL CANCER
Volume 11, Issue 2, Pages 259-267

Publisher

SPRINGER
DOI: 10.1007/s10689-012-9510-1

Keywords

Colorectal cancer; Genetic testing; Hereditary cancer; Microsatellite instability testing; Psychological distress

Funding

  1. Netherlands Digestive Diseases Foundation [SWO 05-07]

Ask authors/readers for more resources

According to the Dutch Guideline on Hereditary Colorectal Cancer published in 2008, patients with recently diagnosed colorectal cancer (CRC) should undergo microsatellite instability (MSI) testing by a pathologist immediately after tumour resection if they are younger than 50 years, or if a second CRC has been diagnosed before the age of 70 years, owing to the high risk of Lynch syndrome (MIPA). The aim of the present MIPAPS study was to investigate general distress and cancer-specific distress following MSI testing. From March 2007 to September 2009, 400 patients who had been tested for MSI after newly diagnosed CRC were recruited from 30 Dutch hospitals. Levels of general distress (SCL-90) and cancer-specific distress (IES) were assessed immediately after MSI result disclosure (T1) and 6 months later (T2). Response rates were 23/77 (30%) in the MSI-positive patients and 58/323 (18%) in the MSI-negative patients. Levels of general distress and cancer-specific distress were moderate. In the MSI-positive group, 27% of the patients had high general distress at T1 versus 18% at T2 (p = 0.5), whereas in the MSI-negative group, these percentage were 14 and 18% (p = 0.6), respectively. At T1 and T2, cancer-specific distress rates in the MSI-positive group and MSI-negative group were 39 versus 27% (p = 0.3) and 38 versus 36% (p = 1.0), respectively. High levels of general distress were correlated with female gender, low social support and high perceived cancer risk. Moderate levels of distress were observed after MSI testing, similar to those found in other patients diagnosed with CRC. Immediately after result disclosure, high cancer-specific distress was observed in 40% of the MSI-positive patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Optimal timing of cholecystectomy after necrotising biliary pancreatitis

Nora D. Hallensleben, Hester C. Timmerhuis, Robbert A. Hollemans, Sabrina Pocornie, Janneke van Grinsven, Sandra van Brunschot, Olaf J. Bakker, Rogier van der Sluijs, Matthijs P. Schwartz, Peter van Duijvendijk, Tessa Romkens, Martijn W. J. Stommel, Robert C. Verdonk, Marc G. Besselink, Stefan A. W. Bouwense, Thomas L. Bollen, Hjalmar C. van Santvoort, Marco J. Bruno

Summary: Cholecystectomy is recommended after an episode of acute biliary pancreatitis to prevent recurrent biliary events. In patients with necrotizing biliary pancreatitis, the optimal timing for surgery is within 8 weeks after discharge.
Article Genetics & Heredity

Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes

Jose Garcia-Pelaez, Rita Barbosa-Matos, Celina Sao Jose, Sonia Sousa, Irene Gullo, Nicoline Hoogerbrugge, Fatima Carneiro, Carla Oliveira

Summary: Tumour risk syndromes (TRS) involve an increased risk of early-onset cancers in familial contexts, with some predisposition to diffuse gastric cancer explained by specific genes, while others remain genetically unsolved. Identifying heritable causes helps define diagnostic testing criteria and classify families for clinical management. The missing heritability in GC-associated TRS may involve a diversity of genes predisposing to other syndromes.

EUROPEAN JOURNAL OF MEDICAL GENETICS (2022)

Correction Gastroenterology & Hepatology

The treatment of acute appendicitis in two age-based groups during COVID-19 pandemic: a retrospective experience in a COVID-19 referral hospital (Nov, 10.1007/s00384-021-04060-z, 2021)

Giorgio Lisi, Michela Campanelli, Maria Rosaria Mastrangeli, Domenico Spoletini, Rosa Menditto, Simona Grande, Massimiliano Boccuzzi, Michele Grande

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2022)

Article Pathology

Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice

Elisabeth M. P. Steeghs, Geraldine R. Vink, Marloes A. G. Elferink, Quirinus J. M. Voorham, Hans Gelderblom, Iris D. Nagtegaal, Katrien Grunberg, Marjolijn J. L. Ligtenberg

Summary: The study in the Netherlands showed an increase in mutation testing rates for CRC patients over time, with anti-EGFR therapy mainly used in KRAS/NRAS wild-type patients after the third treatment line. The national average mutation rate was 63.9%, and NGS-based approaches detected more potential biomarkers.

JOURNAL OF CLINICAL PATHOLOGY (2022)

Article Pathology

Mismatch repair deficiency in early-onset duodenal, ampullary, and pancreatic carcinomas is a strong indicator for a hereditary defect

Valentyna Kryklyva, Lodewijk A. A. Brosens, Monica A. J. Marijnissen-van Zanten, Marjolijn J. L. Ligtenberg, Iris D. Nagtegaal

Summary: The prevalence of dMMR in early-onset duodenal, ampullary, and pancreatic carcinomas was explored, with duodenal carcinomas showing the highest prevalence and most being associated with hereditary cancer syndromes. Universal dMMR testing is recommended in all early-onset duodenal, ampullary, and pancreatic carcinomas to determine the underlying hereditary condition.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2022)

Correction Oncology

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer (vol 126, pg 907, 2022)

Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits, Inge M. van Oort, Winald R. Gerritsen, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Leonie I. Kroeze, Haiko J. Bloemendal, Niven Mehra

BRITISH JOURNAL OF CANCER (2022)

Review Genetics & Heredity

Catch them if you are aware: PTEN postzygotic mosaicism in clinically suspicious patients with PTEN Hamartoma Tumour Syndrome and literature review

Linda A. J. Hendricks, Janneke Schuurs-Hoeijmakers, Isabel Spier, Maaike L. Haadsma, Astrid Eijkelenboom, Kirsten Cremer, Arjen R. Mensenkamp, Stefan Aretz, Janet R. Vos, Nicoline Hoogerbrugge

Summary: This article describes two cases of PTEN mosaicism, suggesting that it may be more common than currently reported. Awareness of PTEN mosaicism is crucial for timely diagnosis and inclusion in cancer surveillance programs, ultimately improving prognosis and life expectancy for affected individuals.

EUROPEAN JOURNAL OF MEDICAL GENETICS (2022)

Article Oncology

Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups

Vera M. Witjes, Joze C. C. Braspenning, Nicoline Hoogerbrugge, Yvonne H. C. M. Smolders, Dorien M. A. Hermkens, Marian J. E. Mourits, Marjolijn J. L. Ligtenberg, Margreet G. E. M. Ausems, Joanne A. de Hullu

Summary: Universal tumor DNA testing in epithelial ovarian cancer patients can serve as an efficient pre-screening tool for hereditary cancer testing and guide treatment choices. However, implementing the Tumor-First workflow requires optimal multidisciplinary collaboration and detailed standardization.

FAMILIAL CANCER (2023)

Article Oncology

Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome

Linda A. J. Hendricks, Nicoline Hoogerbrugge, Arjen R. Mensenkamp, Joan Brunet, Roser Lleuger-Pujol, Hildegunn Hoberg-Vetti, Marianne Tveit Haavind, Giovanni Innella, Daniela Turchetti, Stefan Aretz, Isabel Spier, Marc Tischkowitz, Arne Jahn, Thera P. Links, Maran J. W. Olderode-Berends, Ana Blatnik, Edward M. Leter, D. Gareth Evans, Emma R. Woodward, Verena Steinke-Lange, Violetta C. Anastasiadou, Chrystelle Colas, Marie-Charlotte Villy, Patrick R. Benusiglio, Anna Gerasimenko, Valeria Barili, Maud Branchaud, Claude Houdayer, Bianca Tesi, M. Omer Yazicioglu, Rachel S. van der Post, Janneke H. M. Schuurs-Hoeijmakers, Janet R. Vos, Liselotte P. van Hest, Muriel A. Adank, Floor Duijkers, Maartje Nielsen, Katja C. J. Verbeek, Yvette van Ierland, Jacques C. Giltay

Summary: PTEN Hamartoma Tumor Syndrome (PHTS) is a rare syndrome with a broad phenotypic spectrum, including increased risks of breast, endometrial, and thyroid cancer. This study aimed to provide more accurate and personalized cancer risks. The results showed that PHTS patients, especially females, have a significantly higher risk of breast, endometrial, and thyroid cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients

Gerben Lassche, Sjoerd van Helvert, Astrid Eijkelenboom, Martijn J. H. Tjan, Erik A. M. Jansen, Patricia H. J. van Cleef, Gerald W. Verhaegh, Eveline J. Kamping, Katrien Grunberg, Adriana C. H. van Engen-van Grunsven, Marjolijn J. L. Ligtenberg, Carla M. L. van Herpen

Summary: This research aimed to assess the prevalence of actionable aberrations in salivary gland cancer (SGC) and identified several new gene fusions. Targets for genetically matched therapies were found in different SGC subtypes. This highlights the potential importance of molecular diagnostics in selecting systemic treatment for SGC.

CANCERS (2022)

Article Oncology

Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer

Lisa S. M. Hofste, Maartje J. Geerlings, Daniel von Rhein, Sofie H. Tolmeijer, Marjan M. Weiss, Christian Gilissen, Tom Hofste, Linda M. Garms, Marcel J. R. Janssen, Heidi Rutten, Camiel Rosman, Rachel S. van der Post, Bastiaan R. Klarenbeek, Marjolijn J. L. Ligtenberg

Summary: Ultradeep sequencing-based detection of circulating tumor DNA in preoperative plasma of patients with locally advanced esophageal cancer can predict which patients have a high risk of recurrence after neoadjuvant chemoradiotherapy and surgery.

CANCERS (2022)

Article Oncology

Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome

Lisa Elze, Rachel S. van der Post, Janet R. Vos, Arjen R. Mensenkamp, Mirjam S. C. de Hullu, Iris D. Nagtegaal, Nicoline Hoogerbrugge, Richarda M. de Voer, Marjolijn J. L. Ligtenberg

Summary: This study aims to assess whether other tumor types in individuals with Lynch syndrome share characteristics similar to colorectal and endometrial carcinomas. Analysis of the tumor history of 1745 individuals with Lynch syndrome revealed that more than half of the malignant tumors, apart from colorectal and endometrial carcinomas, exhibit microsatellite instability (MSI-H) and mismatch repair-deficiency (dMMR). Therefore, MSI-H/dMMR testing should be conducted for all malignancies in patients with Lynch syndrome when considering therapy with immune checkpoint inhibitors.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer

Peter H. J. Slootbeek, Joanneke K. Overbeek, Marjolijn J. L. Ligtenberg, Nielka P. van Erp, Niven Mehra

Summary: PARP inhibitors have shown great potential in the treatment of metastatic castration-resistant prostate cancer, with superior responses observed in patients with BRCA1 or BRCA2 gene mutations. Combination therapy with androgen receptor signaling inhibitors can prolong progression-free survival in HRRm patients, but has limited efficacy in the non-HRRm subgroup.

CANCER LETTERS (2023)

No Data Available